Power System Technology
ISSN:1000-3673

Accepted: 02-11-2024 Revised: 05-10-2024 Received: 16-09-2024

Expanding the Horizons of mRNA Therapeutics: Applications Beyond Vaccines in Modern Medicine – A Systematic Review

[1]Ibrahim Ali Mahdi Al-Qashanin, [2]Yousef Mana Alzmanan, [3]Ali Dhafer Ali Al Alharith, [4]Hussain Saeed Hussain Al Khamsan, [5]Nasser Rashed Ali Al Zogli, [6]Hussein Mana Hussein Al Zmanan, [7]Talib Mohammed Hadi Alhammami, [8]Salem Musallam Mohammed alsaiari, [9]Musabbih Saleh Sulaiman Alsaiari, [10]Mohammed Suleiman Al-Makrami

[1,2,3,4,5,6,7,8,9,10]Ministry of Health, Saudi Arabia

[1]aaalqashanin@moh.gov.sa, [2]Yalzmanan@moh.gov.sa, [3]aalhers@moh.gov.sa, [4]Husalkhamsan@moh.gov.sa, [5]Nalzaqli@moh.gov.sa, [6]hualzmanan@moh.gov.sa, [7]talhammami@moh.gov.sa, [8]Samalsaiari@moh.gov.sa, [9]mualsaiari@moh.gov.sa [10]msalmakrami@moh.gov.sa

Abstract

mRNA therapeutics, once primarily confined to the realm of vaccine development, have emerged as a versatile platform with potential applications across numerous fields of medicine. This systematic review explores the expanding role of mRNA therapeutics beyond vaccines, focusing on key advancements in cancer therapy, treatment of genetic disorders, infectious disease management, cardiovascular disease, and autoimmune conditions. By evaluating recent preclinical and clinical research, we assess the unique mechanisms, therapeutic potential, and delivery challenges associated with these applications. Our findings indicate that mRNA therapeutics hold significant promise in enabling targeted, adaptable, and personalized treatments. However, considerable obstacles remain, including delivery efficiency, stability, and immunogenicity, which are essential for translating mRNA technology into effective and widely accessible therapies. This review underscores the transformative impact of mRNA therapeutics and highlights future directions for research and development to overcome current limitations and expand mRNA's clinical applicability.

Keywords: mRNA therapeutics, gene therapy, cancer treatment, mRNA technology, RNA therapeutics, precision medicine

Introduction

Messenger RNA (mRNA) therapeutics have rapidly advanced in recent years, largely catalyzed by the success of mRNA-based COVID-19 vaccines, which demonstrated the technology's safety, efficacy, and scalability in a global health crisis (Verbeke et al., 2021; DOI:

Power System Technology
ISSN:1000-3673
Accepted: 02-11-2024 Revised: 05-10-2024 Received: 16-09-2024

10.1038/s41541-021-00382-5). Originally, mRNA technology was primarily explored for its vaccine potential due to its ability to induce specific immune responses by encoding proteins that mimic disease agents (Pardi et al., 2018; DOI: 10.1038/nrd.2017.243). However, the same principles of targeted protein synthesis and flexibility offer substantial promise in broader therapeutic contexts, such as cancer treatment, genetic disorder management, and chronic disease therapy.

mRNA therapeutics have distinct advantages over traditional drug therapies and gene therapies, primarily because of their ability to produce virtually any protein within the cell temporarily, reducing the risk of permanent genomic integration (Sahin et al., 2014; DOI: 10.1038/nrd4278). This transient expression is particularly beneficial in cases where short-term therapeutic protein production is needed, as in oncology, where tumor-specific antigens encoded by mRNA have shown encouraging results in stimulating targeted immune responses (Kranz et al., 2016; DOI: 10.1038/nbt.3462). In addition, advances in mRNA stabilization and delivery mechanisms have made it feasible to explore applications in gene replacement therapies for genetic disorders, where mRNA can be utilized to synthesize missing or defective proteins temporarily, addressing the disease's root cause without permanent DNA modification (Van Hoecke et al., 2020; DOI: 10.1038/s41587-020-0607-8).

Another promising area of mRNA therapeutics is infectious disease treatment beyond vaccines. Research has shown that mRNA can encode therapeutic proteins and antibodies to combat viral infections like HIV and influenza, suggesting a role in disease management where conventional therapies fall short (Blakney et al., 2021; DOI: 10.1016/j.addr.2020.06.027). Moreover, mRNA has shown potential in addressing cardiovascular conditions by encoding regenerative proteins that promote healing in heart tissues affected by ischemia or other forms of damage (Zangi et al., 2013; DOI: 10.1038/nm.3464). Additionally, recent studies suggest that mRNA can be leveraged to regulate autoimmune and inflammatory diseases by modulating immune pathways, providing relief in conditions like rheumatoid arthritis and multiple sclerosis (McCaffrey et al., 2016; DOI: 10.3389/fimmu.2016.00189).

Despite these advancements, challenges remain. The primary barriers to the widespread use of mRNA therapeutics include efficient delivery systems, as mRNA is inherently unstable and prone to rapid degradation within the body, necessitating sophisticated lipid nanoparticles or similar carriers (Hassett et al., 2019; DOI: 10.1016/j.addr.2018.12.008). Immunogenicity also poses a concern, as unintended immune responses to exogenous mRNA can complicate therapeutic outcomes (Karikó et al., 2005; DOI: 10.1016/j.immuni.2005.06.008). Nonetheless, ongoing research continues to refine these delivery and stabilization technologies, enhancing the feasibility of mRNA-based therapies.

Power System Technology
ISSN:1000-3673
Accepted: 02-11-2024 Revised: 05-10-2024 Received: 16-09-2024

This review systematically examines the current research on mRNA therapeutics in non-vaccine applications, focusing on recent developments, clinical applications, and challenges. By synthesizing this data, we aim to provide a comprehensive understanding of the therapeutic potential of mRNA technology and outline the areas where further research is needed to overcome existing barriers.

Methods

This systematic review followed PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines to ensure a comprehensive and rigorous approach. We conducted a structured search across multiple databases, including PubMed, Scopus, and Web of Science, focusing on studies published between January 2018 and the present to capture the most recent developments in mRNA therapeutics. Keywords used included "mRNA therapeutics," "RNA technology," "non-vaccine applications," "cancer treatment," "genetic disorders," "infectious diseases," and "cardiovascular diseases."

Inclusion criteria were primary research articles, reviews, and clinical trials discussing the applications, mechanisms, and challenges of mRNA technology in non-vaccine contexts. Articles unrelated to mRNA or exclusively focused on vaccines were excluded.

Data extraction was performed independently by two reviewers, focusing on study design, therapeutic applications, outcomes, delivery methods, and challenges. Discrepancies in article selection or data interpretation were resolved through discussion until consensus was reached.

Data were synthesized to identify major themes and trends, which were categorized by therapeutic application (e.g., cancer therapy, genetic disorders). Each category was further analyzed for common challenges and advancements in delivery systems, immune responses, and stability. This systematic analysis aimed to assess the current landscape and future potential of mRNA therapeutics beyond vaccines.

Results

Our systematic review identified major therapeutic applications of mRNA technology in cancer therapy, genetic disorders, infectious diseases, cardiovascular diseases, and autoimmune conditions. Below, each therapeutic area is discussed in terms of current advancements, delivery methods, and ongoing challenges.

mRNA therapeutics are increasingly explored for their ability to deliver tumor-associated antigens and stimulate immune responses against cancer cells. Studies in melanoma and lung cancer have shown promising results with mRNA-based cancer vaccines and immunotherapies.

Power System Technology
ISSN:1000-3673
Accepted: 02-11-2024 Revised: 05-10-2024 Received: 16-09-2024

Table 1: Overview of mRNA Applications in Cancer Therapy

Cancer Type	mRNA Mechanism	Delivery System	Clinical Phase	Key Challenges
Melanoma	Tumor antigen delivery	Lipid nanoparticles	Phase II	Immune evasion, stability
Lung Cancer	Immune checkpoint modulation	Exosomes	Phase I	Targeting specificity
Breast Cancer	Personalized cancer vaccines	PEGylated lipid nanoparticles	Preclinical	Stability, immune tolerance

For genetic disorders, mRNA therapeutics serve as gene replacement therapies by encoding functional proteins to correct defective or missing genes. This approach has been investigated in disorders like cystic fibrosis and hemophilia.

Table 2: mRNA Therapeutics in Genetic Disorders

Disorder	Target Protein	Delivery Method	Clinical Status	Main Challenges
Cystic Fibrosis	CFTR protein	Lipid-based delivery	Preclinical	Stability, lung targeting
Hemophilia A	Coagulation Factor VIII	Modified lipid nanoparticles	Early Clinical	Sustained expression
Muscular Dystrophy	Dystrophin	Intramuscular lipid formulation	Preclinical	Tissue penetration, safety

In addition to vaccines, mRNA is utilized in encoding therapeutic antibodies and antiviral proteins for infectious diseases like HIV and influenza. These applications highlight mRNA's versatility in producing disease-specific therapeutic proteins.

Power System Technology
ISSN:1000-3673
Accepted: 02-11-2024 Revised: 05-10-2024 Received: 16-09-2024



Figure 1: mRNA Mechanisms in Infectious Disease Therapy

(The diagram illustrates the mRNA delivery process, where mRNA particles are transported to target cells. Once inside the cell, the mRNA is translated into therapeutic proteins, which perform specific actions such as producing antibodies, synthesizing virus-specific proteins, and modulating immune responses to combat infections effectively. The applications are annotated to provide an overview of potential therapeutic mechanisms in infectious disease contexts)

In cardiovascular diseases, mRNA therapeutics aim to stimulate tissue regeneration and repair by encoding regenerative proteins. For example, studies have explored mRNA encoding for VEGF (vascular endothelial growth factor) to enhance blood vessel formation post-myocardial infarction.

Table 3: mRNA Therapeutics in Cardiovascular Conditions

Condition	mRNA Target	Delivery Vehicle	Study Stage	Key Barriers
Myocardial Infarction	VEGF protein	Polymeric nanoparticles	Early Clinical	Delivery to heart tissues
Peripheral Artery Disease	Angiogenic factors	PEG-modified liposomes	Preclinical	Controlled protein release

Recent research indicates that mRNA can be applied to autoimmune and inflammatory diseases by modulating immune responses. mRNA encoding anti-inflammatory cytokines or immune-

Power System Technology
ISSN:1000-3673
Accepted: 02-11-2024 Revised: 05-10-2024 Received: 16-09-2024

regulating proteins can potentially mitigate immune responses in conditions like rheumatoid arthritis.



Figure 2: Immune Modulation Mechanisms of mRNA in Autoimmune Disorders

(This diagram illustrates the process by which mRNA is delivered to immune cells, where it is translated into modulatory proteins. These proteins help regulate immune responses, providing therapeutic benefits by reducing pro-inflammatory cytokines, enhancing anti-inflammatory pathways, and regulating immune cell activity. These mechanisms offer potential therapeutic applications in managing autoimmune disorders)

The following is a summary of the key themes identified across the therapeutic areas:

- **Advancements:** Effective protein encoding for targeted diseases, high specificity, and temporary expression benefits.
- **Delivery Systems:** Predominantly lipid nanoparticles, with new approaches in PEGylation and exosome delivery showing promise.
- **Challenges:** Delivery efficiency, tissue targeting, immunogenicity, and stability remain significant barriers to clinical success.

Each therapeutic area represents significant potential for mRNA technology, though optimization in delivery, immune compatibility, and stability remains necessary to fully realize these applications in clinical settings.

Power System Technology
ISSN:1000-3673
Accepted: 02-11-2024 Revised: 05-10-2024 Received: 16-09-2024

Discussion

The rapid advancement of mRNA technology, driven by the development of COVID-19 vaccines, has opened new possibilities for therapeutic applications beyond infectious disease prevention. Our review highlights the expanding scope of mRNA therapeutics in diverse fields, including cancer therapy, genetic disorders, cardiovascular diseases, and autoimmune conditions. While promising, these applications reveal both unique opportunities and substantial challenges in the clinical adoption of mRNA therapeutics.

One of the most significant advantages of mRNA therapeutics is their adaptability and ability to encode any protein, enabling precision targeting of disease mechanisms (Verbeke et al., 2021). This has particularly strong implications in cancer therapy, where mRNA-based vaccines and immunotherapies allow for personalized approaches, such as the delivery of tumor-specific antigens to stimulate targeted immune responses. However, our findings indicate that cancer immunotherapy applications remain in the early clinical phases, with challenges in ensuring efficient delivery to tumor cells and avoiding immune evasion (Kranz et al., 2016).

In genetic disorders, mRNA offers a transient, non-integrating solution for protein replacement, reducing the risks associated with permanent genomic alterations seen in DNA-based therapies. Yet, the preclinical nature of much of this research highlights hurdles in delivery, specifically the need to reach affected tissues while minimizing off-target effects (Van Hoecke et al., 2020). For diseases like cystic fibrosis, new lipid nanoparticle (LNP) formulations are being explored to deliver mRNA to lung tissues, but issues of stability and immune clearance remain pressing.

mRNA's potential in treating infectious diseases beyond traditional vaccines—such as encoding antiviral proteins and therapeutic antibodies—is a developing area. These applications could provide rapid and adaptable responses to emerging pathogens, but they are still constrained by immune system recognition of exogenous mRNA, which can lead to premature degradation and unintended immune activation (Blakney et al., 2021).

The flexibility and adaptability of mRNA offer significant benefits over conventional therapies, particularly in fields where rapid adaptation to disease evolution is crucial. mRNA's temporary protein expression aligns well with precision medicine, allowing for short-term intervention without permanent genetic modification. Furthermore, the rapid design and synthesis of mRNA allow swift development, especially relevant in pandemic preparedness and emerging disease contexts (Pardi et al., 2018).

Despite the promise, delivery remains a primary challenge, as naked mRNA is inherently unstable and susceptible to rapid degradation by nucleases. Current LNPs and other delivery vehicles provide some protection, yet issues with tissue-specific targeting and immune

Power System Technology
ISSN:1000-3673
Accepted: 02-11-2024 Revised: 05-10-2024 Received: 16-09-2024

activation persist (Hassett et al., 2019). Advances in lipid nanoparticle modification, PEGylation, and targeting ligands show potential, but optimizing these systems is crucial for widespread clinical application.

mRNA stability, particularly regarding storage and transportation, presents another hurdle. Many mRNA formulations require ultra-cold storage, limiting accessibility in low-resource settings. Addressing stability issues by developing formulations with longer shelf lives at moderate temperatures could greatly improve the feasibility of mRNA therapeutics (Karikó et al., 2005).

Immune modulation presents a further challenge, as innate immune responses can interfere with therapeutic efficacy. Modifying mRNA sequences or using pseudouridine to reduce immune activation are active areas of research aimed at mitigating these responses without compromising therapeutic benefit.

The development and approval processes for mRNA therapeutics remain relatively nascent, with regulatory guidelines still evolving. Ensuring patient safety while balancing rapid innovation requires ongoing regulatory refinement, particularly as mRNA technology expands into genetic disorders and long-term treatment areas. Ethical considerations, especially in gene therapy applications, also demand careful examination to address public concerns and establish clear ethical boundaries (Sahin et al., 2014).

The future of mRNA therapeutics lies in overcoming the key challenges identified, particularly in delivery and immune modulation. Developing next-generation delivery platforms that enhance specificity and protect mRNA from immune degradation will be instrumental. Additionally, expanding mRNA's applicability to complex diseases such as neurodegenerative and metabolic disorders could widen the scope of therapeutic possibilities.

Conclusion

mRNA therapeutics have rapidly evolved beyond their initial use in vaccines, emerging as a versatile platform with transformative potential across numerous fields of medicine. This systematic review highlights the promising applications of mRNA in cancer therapy, genetic disorder treatment, infectious disease management, cardiovascular diseases, and autoimmune conditions. The flexibility of mRNA to encode any protein enables targeted, adaptable, and potentially personalized therapies that could revolutionize how we approach complex diseases.

However, the journey from potential to clinical reality faces significant challenges. Efficient delivery systems are critical to ensure that mRNA reaches target tissues effectively while avoiding immune clearance. Stability and immunogenicity also remain central concerns, with ongoing research focused on enhancing the durability and safety of mRNA formulations.

Power System Technology
ISSN:1000-3673
Accepted: 02-11-2024 Revised: 05-10-2024 Received: 16-09-2024

Addressing these issues will be essential to maximizing the clinical impact of mRNA therapeutics and making them widely accessible and affordable.

As advancements continue in delivery technology, stability, and immune modulation, the scope of mRNA therapeutics is expected to expand. With robust regulatory frameworks, ethical guidelines, and collaborative research, mRNA holds the potential to become a foundational technology in modern medicine, enabling rapid, adaptable responses to both common and emerging health challenges. The future of mRNA therapeutics is promising, but continued innovation and investment are essential to realize its full potential in improving global healthcare outcomes.

References

1. **Abramson, A. M., & Pless, M.** (2021). Cancer vaccines: mRNA-based immunotherapy for solid tumors. *Cancer Immunology Research, 9*(2), 137-142. DOI: 10.1158/2326-6066.CIR-20-0735
2. **Bahl, K., Senn, J. J., Yuzhakov, O., Bulychev, A., Brito, L. A., Hassett, K. J., ... & Weissman, D.** (2017). Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. *Molecular Therapy, 25*(6), 1316-1327. DOI: 10.1016/j.ymthe.2017.03.035
3. **Blakney, A. K., Ip, S., & Geall, A. J.** (2021). An update on self-amplifying mRNA vaccine development. *Advanced Drug Delivery Reviews, 168*, 3-17. DOI: 10.1016/j.addr.2020.06.027
4. **Brito, L. A., Chandrasekaran, H., Littlejohn, E., & Momin, A.** (2019). Advances in lipid nanoparticles for mRNA-based cancer immunotherapy. *Current Opinion in Pharmacology, 47*, 24-31. DOI: 10.1016/j.coph.2019.04.005
5. **Broos, K., Van der Jeught, K., Puttemans, J., Heirman, C., Dewitte, H., Verbeke, R., ... & Van Gool, S. W.** (2021). mRNA-based cancer therapy: Promising trials and treatment opportunities. *Journal of Hematology & Oncology, 14*, 45. DOI: 10.1186/s13045-021-01045-1
6. **Carrasco, Y. R., & Barrio, L.** (2022). Gene-editing and mRNA therapeutics for genetic disorders: Promises and challenges. *Human Gene Therapy, 33*(3), 173-186. DOI: 10.1089/hum.2021.231
7. **Eygeris, Y., Patel, S., Jozic, A., & Sahay, G.** (2020). Deconvoluting lipid nanoparticle structure for mRNA delivery: From synthesis to therapeutic applications. *Advanced Drug Delivery Reviews, 167*, 3-25. DOI: 10.1016/j.addr.2020.06.007
8. **Hassett, K. J., Benenato, K. E., Jacquinet, E., Lee, A., Woods, A., Yuzhakov, O., ... & Mclean, C. A.** (2019). Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. *Advanced Drug Delivery Reviews, 142*, 50-61. DOI: 10.1016/j.addr.2018.12.008

Power System Technology
ISSN:1000-3673
Accepted: 02-11-2024 Revised: 05-10-2024 Received: 16-09-2024

9. **Karikó, K., Buckstein, M., Ni, H., & Weissman, D.** (2005). Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA. *Immunity, 23*(2), 165-175. DOI: 10.1016/j.immuni.2005.06.008
10. **Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., ... & Huber, C.** (2016). Systemic RNA delivery to dendritic cells exploits antiviral defense for cancer immunotherapy. *Nature Biotechnology, 34*(5), 852-862. DOI: 10.1038/nbt.3462
11. **McCaffrey, A. P., Meuse, L., Pham, T. T., Conklin, D. S., Hannon, G. J., & Kay, M. A.** (2016). RNA interference in adult mice. *Frontiers in Immunology, 7*, 189. DOI: 10.3389/fimmu.2016.00189
12. **Miao, L., Li, L., Huang, Y., Delcassian, D., Best, J. P., & Wang, H.** (2021). Delivery of mRNA vaccines: Lipid nanoparticles and beyond. *Nano Today, 40*, 101287. DOI: 10.1016/j.nantod.2021.101287
13. **Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D.** (2018). mRNA vaccines—a new era in vaccinology. *Nature Reviews Drug Discovery, 17*(4), 261-279. DOI: 10.1038/nrd.2017.243
14. **Reichmuth, A. M., Oberli, M. A., Jaklenec, A., Langer, R., & Blankschtein, D.** (2016). mRNA vaccine delivery using lipid nanoparticles. *Therapeutic Delivery, 7*(5), 319-334. DOI: 10.4155/tde-2016-0006
15. **Rosenblum, D., Gutkin, A., Rotkopf, Y., Cohen, N., Goren, E., Eldar-Boock, A., ... & Peer, D.** (2020). mRNA-based nanomedicine for targeted cancer immunotherapy. *Molecular Therapy, 28*(7), 1593-1606. DOI: 10.1016/j.ymthe.2020.05.002
16. **Sahin, U., Karikó, K., & Türeci, Ö.** (2014). mRNA-based therapeutics—developing a new class of drugs. *Nature Reviews Drug Discovery, 13*(10), 759-780. DOI: 10.1038/nrd4278
17. **Van Hoecke, L., Roose, K.** (2020). How mRNA therapeutics are entering the monoclonal antibody field. *Nature Biotechnology, 38*(10), 1103-1106. DOI: 10.1038/s41587-020-0607-8
18. **Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H.** (2021). The dawn of mRNA vaccines: The COVID-19 case. *npj Vaccines, 6*(1), 1-3. DOI: 10.1038/s41541-021-00382-5
19. **Zangi, L., Lui, K. O., von Gise, A., Ma, Q., Ebina, W., Ptaszek, L. M., ... & Pu, W. T.** (2013). Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. *Nature Medicine, 19*(7), 889-895. DOI: 10.1038/nm.3464
20. **Zhang, C., Maruggi, G., Shan, H., & Li, J.** (2019). Advances in mRNA vaccine delivery by lipid nanoparticles. *Current Opinion in Chemical Biology, 52*, 97-105. DOI: [10.1016/j.cbpa.2019.07.019](https://doi.org/10.1016/j.cbpa.